Major Small and Large Bowel Procedures with MCC DRG Reimbursement

Summary & Overview

Major Small and Large Bowel Procedures with MCC: Inpatient Reimbursement Overview

DRG 329 encompasses major small and large bowel procedures performed in the presence of a Major Complication or Comorbidity and is used to classify high-acuity surgical admissions for inpatient reimbursement. It matters for Medicare payment because the presence of a Major Complication or Comorbidity increases the Diagnosis-Related Group severity assignment and typically results in higher inpatient reimbursement to reflect greater resource use.

Major Small and Large Bowel Procedures with MCCDRG Major Small and Large Bowel Procedures with MCCDRG 329Diagnosis-Related GroupInpatient ReimbursementMedicareColorectal SurgeryGeneral SurgeryBowel ResectionSurgical Complications

DRG 329 Overview

DRG 329 covers major small and large bowel surgical procedures when a Major Complication or Comorbidity is present, typically including extensive resections, anastomoses, or procedures for perforation, ischemia, obstruction, or severe inflammatory disease with significant physiologic instability. This Diagnosis-Related Group groups higher-resource cases with critical intraoperative or postoperative complexity, which increases allowable Medicare inpatient reimbursement relative to less complex bowel procedure groups. Accurate capture of principal procedure codes and documented Major Complication or Comorbidity drives appropriate payment assignment. The grouping reflects expected higher resource use, longer inpatient stays, and greater clinical intensity.

National Payment Rates

Across commercial payers the negotiated rate range for DRG 329 spans from $40K (BCBS min) up to $170K (Anthem max), with payer medians clustered between $42K and $80K. The widest spread between payer minimums and maximums is seen with Anthem versus BCBS at roughly $130K. See the table and chart below for payer-specific quartiles and distribution details.

Mean Rates by Payer — National — DRG 329

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 329. These figures reflect Medicare FFS payment experience at the national level for 2023.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

In Alaska, rates for DRG 329 span from a low median of $71K (Blue Cross Blue Shield/Anthem) to a high median of $110K (Cigna), with mean values ranging roughly $64K–$110K across payers. The most notable deviation versus national averages is Cigna’s substantially higher median of $110K compared with typical national medians around $70K–$80K. See the table and chart below for payer-specific distributions.

Key Insights for Alaska

Highest payer: Cigna with a median of $110K and a mean of $110K, representing the top compensation level in the state.
Lowest payer: BCBS/Anthem (both share the same AK benchmarks) with a median of $71K and a mean of $64K, representing the low end of the state range.
Meaningful deviation: Cigna’s median of $110K sits well above the AK medians for BCBS/Anthem ($71K) and is also notably higher than national medians for comparable payers, indicating a pronounced state-level spread.

Clinical Trials

Acute perioperative intervention trials focusing on strategies to reduce surgical morbidity and mortality in patients undergoing major small and large bowel resections for emergent or complicated disease (for example ischemic bowel, perforation, or obstructive malignancy). These studies enroll high-acuity inpatients typically with sepsis risk, hemodynamic instability, or contamination of the peritoneal cavity and test interventions such as optimized fluid resuscitation protocols, timing of source control, intraoperative techniques to reduce anastomotic leak, or standardized sepsis bundles. Findings are directly relevant to surgeons, intensivists, and hospital payers because improvements can reduce ICU days, reoperation rates, complication-related coding changes (MCC attribution), and overall inpatient costs.
Comparative effectiveness trials evaluating surgical approaches and perioperative care pathways for elective or semi-elective major bowel procedures in patients with underlying malignancy, inflammatory bowel disease, or complex diverticular disease. These studies compare open versus minimally invasive techniques, primary anastomosis versus staged procedures with diversion, or enhanced recovery after surgery (ERAS) protocols, and typically enroll patients who are stable enough for definitive operations but have high comorbidity burdens. Results inform decisions about procedure selection and care standardization that affect length of stay, readmission risk, and resource utilization—key concerns for clinicians and payers seeking to optimize outcomes while controlling reimbursement-driven metrics.
Post-discharge and outcomes research focusing on long-term functional recovery, stoma reversal timing, and health-care utilization among survivors of major small and large bowel surgery who incurred major complications during the index admission. These cohort or pragmatic studies follow patients after discharge to measure readmissions, persistent organ dysfunction, return to baseline nutrition and mobility, and durable quality-of-life outcomes, often stratified by presence of MCC during the hospitalization. Providers and payers rely on this evidence to design transitional care programs, determine follow-up intensity, and predict downstream costs associated with chronic care needs or late complications stemming from the index DRG episode.

Other Digestive System Diagnoses with MCC: Inpatient Reimbursement Overview

370-MAJOR-ESOPHAGEAL-DISORDERS-WITHOUT-CC-MCC

Major Esophageal Disorders without CC/MCC: Inpatient Reimbursement Overview

372-MAJOR-GASTROINTESTINAL-DISORDERS-AND-PERITONEAL-INFECTIONS-WITH-CC

Major Gastrointestinal Disorders and Peritoneal Infections with CC: Inpatient Reimbursement Overview

328-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITHOUT-CC-MCC

Stomach, Esophageal and Duodenal Procedures without CC/MCC: Inpatient Reimbursement Overview

394-OTHER-DIGESTIVE-SYSTEM-DIAGNOSES-WITH-CC

Other Digestive System Diagnoses with CC: Inpatient Reimbursement Overview

348-ANAL-AND-STOMAL-PROCEDURES-WITH-CC

Anal and Stomal Procedures with CC: Inpatient Reimbursement Overview

344-MINOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-MCC

Minor Small and Large Bowel Procedures with MCC: Inpatient Reimbursement Overview

336-PERITONEAL-ADHESIOLYSIS-WITH-CC

Peritoneal Adhesiolysis with CC: Inpatient Reimbursement Overview

331-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITHOUT-CC-MCC

Major Small and Large Bowel Procedures without CC/MCC: Inpatient Reimbursement Overview

354-HERNIA-PROCEDURES-EXCEPT-INGUINAL-AND-FEMORAL-WITH-CC

Hernia Procedures Except Inguinal and Femoral with CC: Inpatient Reimbursement Overview

Showing 1–10 of 57

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$42K	$200K	$36K	31K